Search results for "Prospective Studies"

showing 10 items of 3070 documents

Genome-wide Association Study Identifies Genetic Variants Associated With Early and Sustained Response to (Pegylated) Interferon in Chronic Hepatitis…

2019

Wong, Grace LH/0000-0002-2863-9389; Wong, Vincent WS/0000-0003-2215-9410; Mangia, A/0000-0002-2600-3555; Brahmania, Mayur/0000-0002-4671-1479; Chan, Henry Lik-Yuen/0000-0002-7790-1611; Brouwer, Willem Pieter/0000-0001-8713-1481; Feld, Jordan/0000-0003-2640-2211; Tanwandee, Tawesak/0000-0001-7634-0843; Jaroszewicz, Jerzy/0000-0003-0139-4753; Chuaypen, Natthaya/0000-0002-5415-510X

0301 basic medicineMicrobiology (medical)AdultMaleHBsAgHepatitis B virusSettore MED/09 - Medicina InternaGenotyping TechniquesGenome-wide association studymedicine.disease_causePeripheral blood mononuclear cellAntiviral Agents03 medical and health sciences0302 clinical medicineHepatitis B ChronicSDG 3 - Good Health and Well-beingPegylated interferonInterferonmedicineHumansGWASchronic hepatitis BgeneticsProspective StudiespeginterferonArticles and CommentariesHepatitis B virusresponsebusiness.industryInterleukinInterferon-alphaMiddle Aged3. Good health030104 developmental biologyInfectious DiseasesHBeAgImmunologyMultivariate Analysis030211 gastroenterology & hepatologyFemaleInterferonsbusinessmedicine.drugGenome-Wide Association StudyClinical Infectious Diseases
researchProduct

No effect of vancomycin MIC ≥ 1.5 mg/L on treatment outcome in methicillin-susceptible Staphylococcus aureus bacteraemia

2018

International audience; The vancomycin minimum inhibitory concentration (MIC) has been shown to affect the outcome of methicillin-susceptible Staphylococcus aureus (MSSA) bacteraemia. In this study, the outcomes of patients with MSSA bacteraemia with a vancomycin MIC ≥ 1.5 mg/L were assessed. A prospective cohort of patients with MSSA bacteraemia in two tertiary-care hospitals was collected. The vancomycin MIC was determined by Etest. Staphylococcus aureus strains were categorised as low (<1.5 mg/L) or high (≥1.5 mg/L) vancomycin MIC. First- and second-line treatments were recorded and classified as optimal, appropriate and inappropriate. The primary endpoint was 30-day mortality. A total o…

0301 basic medicineMicrobiology (medical)MaleMethicillin-Resistant Staphylococcus aureusmedicine.medical_specialtyStaphylococcus aureusmedicine.drug_classmedicine.medical_treatment030106 microbiologyAntibioticsBacteremiaMicrobial Sensitivity Testsmedicine.disease_cause03 medical and health sciencesMinimum inhibitory concentrationVancomycin[ SDV.MP ] Life Sciences [q-bio]/Microbiology and ParasitologyInternal medicine[ SDV.MHEP ] Life Sciences [q-bio]/Human health and pathologymedicineHumansPharmacology (medical)Prospective StudiesMortalityProspective cohort studyEtestDialysisAgedAged 80 and overMinimum inhibitory concentrationbusiness.industryGeneral MedicineMiddle AgedStaphylococcal Infectionsbiochemical phenomena metabolism and nutritionbacterial infections and mycoses3. Good healthAnti-Bacterial Agents[SDV.MP]Life Sciences [q-bio]/Microbiology and ParasitologyInfectious DiseasesStaphylococcus aureusCatheter-Related InfectionsVancomycinBacteraemiaFemaleMethicillin Susceptible Staphylococcus Aureusbusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologymedicine.drug
researchProduct

Neisseria gonorrhoeae antimicrobial resistance in Spain: a prospective multicentre study.

2021

Abstract Objectives Gonococcal infection is one of the most reported sexually transmitted infections and antimicrobial resistance in Neisseria gonorrhoeae (NG) is challenging for the treatment of this infection. This observational study aimed to describe antimicrobial resistance of NG and epidemiological data from patients with gonococcal infection in eight regions of Spain, for updating the local therapeutic guidelines. Methods MICs of penicillin, cefixime, ceftriaxone, azithromycin, ciprofloxacin, fosfomycin and gentamicin were determined by Etest for all NG isolates recovered from 1 April 2018 to 30 September 2019 from 10 hospitals in Spain. Resistance determinants were identified using …

0301 basic medicineMicrobiology (medical)Malemedicine.medical_specialty030106 microbiologyMicrobial Sensitivity TestsFosfomycinAzithromycinAzithromycinmedicine.disease_cause03 medical and health sciencesGonorrheaSexual and Gender Minorities0302 clinical medicineAntibiotic resistanceCiprofloxacinInternal medicineDrug Resistance BacterialmedicineHumansPharmacology (medical)030212 general & internal medicineProspective StudiesHomosexuality MaleEtestPharmacologybusiness.industryCeftriaxoneNeisseria gonorrhoeaeAnti-Bacterial AgentsPenicillinCiprofloxacinInfectious DiseasesSpainNeisseria gonorrhoeaebusinessCefiximemedicine.drugThe Journal of antimicrobial chemotherapy
researchProduct

Factors associated with 12 week case-fatality in Staphylococcus aureus bacteraemia: a prospective cohort study

2016

International audience; Staphylococcus aureus bacteraemia (SAB) is a frequent and deadly disease. Given the lack of a randomized trial, optimal first-line antibiotic treatment is still debated. Our aim was to identify prognostic factors in SAB patients and to analyse the impact of first-line antibiotics. The VIRSTA prospective cohort study was conducted in eight tertiary care centres in France. Consecutive incident adults in whom a blood culture drawn in participating centres grew S. aureus between April 2009 and October 2011 were prospectively followed for 12 weeks. Factors associated with 12-week case-fatality were identified by multivariate logistic regression. We enrolled 2091 patients …

0301 basic medicineMicrobiology (medical)Malemedicine.medical_specialtyStaphylococcus aureusmedicine.drug_class030106 microbiologyAntibioticsBacteremiaPenicillinsPrognostic factorsTertiary Care Centers03 medical and health sciencesInterquartile range[ SDV.MP ] Life Sciences [q-bio]/Microbiology and ParasitologyVancomycinInternal medicineCase fatality ratemedicineHumansBlood cultureProspective StudiesProspective cohort study[SDV.MP] Life Sciences [q-bio]/Microbiology and ParasitologyAgedAntistaphylococcal penicillinsCross Infectionmedicine.diagnostic_testbusiness.industrySeptic shockGeneral MedicineMiddle AgedStaphylococcal Infectionsmedicine.diseasePrognosisSurvival Analysis3. Good healthSurgeryInfectious Diseases[SDV.MP]Life Sciences [q-bio]/Microbiology and ParasitologyVancomycinBacteraemiaAntistaphylococcal penicillinFemaleFrancebusinessmedicine.drug
researchProduct

Association between DNA methylation and ADHD symptoms from birth to school age: a prospective meta-analysis

2020

Funder: Gouvernement du Canada | Canadian Institutes of Health Research (Instituts de Recherche en Santé du Canada); doi: https://doi.org/10.13039/501100000024

0301 basic medicineOncology3124 Neurology and psychiatryEpigenesis GeneticACTIVATION0302 clinical medicine3123 Gynaecology and paediatricsPregnancyProspective StudiesProspective cohort studyChildRISK0303 health sciencesSchoolsATTENTION-DEFICIT/HYPERACTIVITY DISORDERMethylation3. Good healthPsychiatry and Mental healthMeta-analysisChild PreschoolDNA methylation/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_beingBiomarker (medicine)FemalePACKAGEmedicine.medical_specialtyAdolescent515 PsychologyArticlelcsh:RC321-571Cellular and Molecular Neuroscience03 medical and health sciencesSDG 3 - Good Health and Well-beingInternal medicinemedicineGeneticsAttention deficit hyperactivity disorderHumansEpigeneticslcsh:Neurosciences. Biological psychiatry. NeuropsychiatryBiological Psychiatry030304 developmental biologyGenetic associationPregnancybusiness.industryInfant NewbornPERFORMANCEDNA Methylationmedicine.diseaseGENE030104 developmental biologyAttention Deficit Disorder with HyperactivityCOHORT PROFILEEtiologybusinessPsychiatric disorders030217 neurology & neurosurgery
researchProduct

Cetuximab, fluorouracil and cisplatin with or without docetaxel for patients with recurrent and/or metastatic squamous cell carcinoma of the head and…

2019

Abstract Background The combination of cisplatin, 5-fluorouracil (5-FU) and cetuximab (PFC) is the reference first-line treatment for recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN). We analysed whether treatment intensification by the addition of docetaxel to PFC improved efficacy in R/M SCCHN. Methods A total of 180 patients with R/M SCCHN (1:1) were assigned to receive either cisplatin (40 mg/m2), docetaxel (40 mg/m2) and 5-FU (2000 mg/m2) at days 1 and 8 and cetuximab (400/250 mg/m2) at days 1, 8 and 15 (DPFC) or standard cisplatin (100 mg/m2) at day 1, 5-FU (1000 mg/m2) at days 1–4 and cetuximab (400/250 mg/m2) at days 1, 8 and 15 (PFC). Chemotherapy was…

0301 basic medicineOncologyAdultMaleCancer Researchmedicine.medical_specialtymedicine.medical_treatmentMedizinCetuximabDocetaxelDisease-Free SurvivalDrug Administration Schedule03 medical and health sciences0302 clinical medicineInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansProspective StudiesAgedCisplatinChemotherapyCetuximabbusiness.industrySquamous Cell Carcinoma of Head and NeckHead and neck cancerHazard ratioMiddle AgedInterim analysismedicine.disease030104 developmental biologyOncologyDocetaxelFluorouracil030220 oncology & carcinogenesisFemaleFluorouracilCisplatinbusinessmedicine.drug
researchProduct

Autologous stem cell ovarian transplantation to increase reproductive potential in patients who are poor responders.

2018

Objective: To evaluate effects of autologous stem cell ovarian transplant (ASCOT) on ovarian reserve and IVF outcomes of women who arc poor responders with very poor prognosis. Design: Prospective observational pilot study. Setting: University hospital. Patient(s): Seventeen women who are poor responders. Intervention(s): Ovarian infusion of bone marrow-derived stem cells. Main Outcome Measure(s): Serum antimullerian hormone levels and antral follicular count (AFC), punctured follicles, and oocytes retrieved after stimulation (controlled ovarian stimulation) were measred. Apheresis was analyzed for growth factor concentrations. Result(s): The ASCOT resulted in a significant improvement in A…

0301 basic medicineOncologyAdultmedicine.medical_specialtyPoor responderPilot ProjectsFertilization in VitroTransplantation Autologousovarian reserve03 medical and health sciencesFollicle0302 clinical medicinebone marrow-derived stem cell transplantInternal medicineFollicular phasemedicineAMHHumansProspective StudiesOvarian reserveOvarian ReservePregnancy030219 obstetrics & reproductive medicinebusiness.industryReproductionOvaryObstetrics and Gynecologymedicine.diseaseAntral follicleOocyteClinical trial030104 developmental biologymedicine.anatomical_structureTreatment OutcomeReproductive Medicineantral follicular countFemaleStem cellbusinessInfertility FemaleStem Cell TransplantationFertility and sterility
researchProduct

Short term quality of life with epirubicin-fluorouracil-cyclophosphamid (FEC) and sequential epirubicin/cyclophosphamid-docetaxel (EC-DOC) chemothera…

2016

Abstract Background The recommendation for adjuvant dose-dense chemotherapy in high risk primary breast cancer is heterogeneous among guidelines. Understanding the impact on QoL is thereby a crucial factor, especially if the benefit is potentially low. This study aims to assess QoL as a secondary outcome in the prospective randomized multi-center ADEBAR trial. Methods QoL was assessed at baseline (t1), before cycle 4 FEC and cycle 5 EC-DOC (t2), 4 weeks after chemotherapy (t3) and 6 weeks after radiation (t4) using the European Organization for Research and Treatment for Cancer (EORTC) Quality of Life Core Questionnaire (QLQ-C30) and the Breast Cancer-Specific Module (QLQ-BR23). Results 130…

0301 basic medicineOncologyAdultmedicine.medical_specialtyTime FactorsAdolescentNauseamedicine.medical_treatmentBreast NeoplasmsDocetaxelDrug Administration Schedule03 medical and health sciencesYoung Adult0302 clinical medicineBreast cancerQuality of lifeInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansProspective StudiesProspective cohort studyCyclophosphamideAgedEpirubicinChemotherapybusiness.industryGeneral MedicineMiddle Agedmedicine.diseasehumanitiesSurgery030104 developmental biologyTreatment OutcomeDocetaxelFluorouracilChemotherapy Adjuvant030220 oncology & carcinogenesisQuality of LifeSurgeryFemaleTaxoidsFluorouracilmedicine.symptombusinessmedicine.drugEpirubicinBreast (Edinburgh, Scotland)
researchProduct

M-TRAP: Safety and performance of metastatic tumor cell trap device in advanced ovarian cancer patients

2021

Objective. Despite radical surgery and chemotherapy, most patients with ovarian cancer die due to disease progression. M-Trap is an implantable medical device designed to capture peritoneal disseminated tumor cells with the aim to focalize the disease. This trial analyzed the safety and performance of the device. Methods. This first-in-human prospective, multi-center, non-blinded, single-arm study enrolled 23 women with high-grade serous advanced ovarian cancer. After primary or interval debulking surgery, 3 M-Trap devices were placed in the peritoneum of the abdominal cavity. 18-months post-implantation or at disease progression, devices were initially removed by laparoscopy. The primary s…

0301 basic medicineOncologyAdultmedicine.medical_specialtymedicine.medical_treatmentPerformanceDiseaseCarcinoma Ovarian Epithelial03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansCytoreductive surgeryProspective StudiesRadical surgeryNeoplasm MetastasisAdverse effectLaparoscopyPeritoneal NeoplasmsAgedOvarian NeoplasmsChemotherapymedicine.diagnostic_testbusiness.industryM-Trap deviceObstetrics and GynecologyCytoreduction Surgical ProceduresMiddle AgedDebulkingmedicine.diseaseSerous fluid030104 developmental biologyTreatment OutcomeOncologySpain030220 oncology & carcinogenesisAdvanced ovarian cancerFemaleNeoplasm Recurrence LocalRecurrent ovarian cancerSafetyOvarian cancerbusinessPeritoneal carcinomatosis
researchProduct

Circulating Molecular Chaperones in Subjects with Amnestic Mild Cognitive Impairment and Alzheimer’s Disease: Data from the Zabùt Aging Project

2022

Molecular chaperones play essential roles in many processes such as cell differentiation, tissue homeostasis, and organ remodeling. Recent data indicate that chaperones can act as cytoprotectants for brain cells during the progression of neurodegenerative diseases, including Alzheimer’s disease (AD). However, very few data on the levels of chaperones in dementia, including its prodromal phases, have been reported. In this study, we used biological samples and epidemiological data collected during the Zabùt Aging Project (a prospective, community-based, cohort study of normal/pathological aging conducted in Sicily, Italy, with a follow-up of ten years) to determine if there is an association…

0301 basic medicineOncologyAgingmedicine.medical_specialtySettore MED/09 - Medicina InternaHsp90DiseaseNeuropsychological Testsmedicine.disease_causeHsp70Cohort Studies03 medical and health sciences0302 clinical medicineAlzheimer DiseaseInternal medicineEpidemiologyoxidative stressHumansMedicineDementiaCognitive DysfunctionProspective StudiesPathologicalTissue homeostasiscognitive impairmentSettore MED/04 - Patologia Generalebusiness.industryGeneral NeuroscienceNeurodegenerationneurodegenerationGeneral Medicinemolecular chaperoneHsp60medicine.diseasePsychiatry and Mental healthClinical Psychology030104 developmental biologySettore MED/26 - NeurologiaGeriatrics and GerontologybusinessAlzheimer’s disease030217 neurology & neurosurgeryOxidative stressMolecular ChaperonesCohort studyJournal of Alzheimer's Disease
researchProduct